OPS
PTGX icon

Orion Portfolio Solutions’s Protagonist Therapeutics PTGX Stock Holding History

Orion Portfolio Solutions’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$326K Buy
+6,731
New +$282K ﹤0.01% 1590
2024
Q4 		– Sell
-6,114
Closed -$275K – 1891
2024
Q3 		$275K Sell
6,114
-1,274
-17% -$51.5K ﹤0.01% 1553
2024
Q2 		$256K Buy
+7,388
New +$216K ﹤0.01% 1528

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Orion Portfolio Solutions's PTGX Position: Q1 2025 in Review

Orion Portfolio Solutions opened a new position in Protagonist Therapeutics (PTGX) in Q1 2025: 6,731 shares worth $326K. The stake represents ﹤0.01% of the portfolio and ranks #1590 among its holdings. This is a return to the name: Orion Portfolio Solutions previously reported a position in PTGX as recently as Q3 2024.

Orion Portfolio Solutions first reported a position in PTGX in Q2 2024 and has held it in 3 quarters since. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Orion Portfolio Solutions held 6,731 shares of Protagonist Therapeutics worth $326K as of Q1 2025.
  • Protagonist Therapeutics was a new Orion Portfolio Solutions position in Q1 2025.
  • Protagonist Therapeutics made up ﹤0.01% of Orion Portfolio Solutions's portfolio in Q1 2025, its #1590 holding.
  • Orion Portfolio Solutions first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Orion Portfolio Solutions's 13F filing for Q1 2025, filed 14 May 2025.